Insta

Delhi HC Quashes Centre’s Ban On 344 FDC Medicines After Pharma Company Petitions

Swarajya Staff

Dec 01, 2016, 04:35 PM | Updated 04:35 PM IST


An Indian pharmacy shop assistant counts a strip of tablets. Photo credit: DESHAKALYAN CHOWDHURY/AFP/Getty Images
An Indian pharmacy shop assistant counts a strip of tablets. Photo credit: DESHAKALYAN CHOWDHURY/AFP/Getty Images

The Delhi High Court on Thursday (1 December) quashed the centre's notification to ban 344 fixed dose combination (FDC) medicines. The brands included D'Cold Total, Corex cough syrup and Vicks Action 500, among others.

Justice R S Endlaw, allowing the 454 pleas filed by the pharma companies, quashed the centre's notification issued on 10 March. Companies like Pfizer, Glenmark, Procter and Gamble, Reckitt Benckiser, Cipla and others had moved the court against the government’s decision. The court had granted stay on the notification.

The government had told the court that FDC medicines sold by pharma majors "endanger patient safety". It had banned the drugs on the ground that they involve risk to humans and, therefore, needed to be withdrawn immediately and contended that safer alternatives were available.

The pharma companies had argued that the ban order was passed without considering clinical data and had termed the government's claim as absurd.

With inputs from IANS


Get Swarajya in your inbox.


Magazine


image
States